Pamela F Weiss1, Timothy G Brandon2, Meghan E Ryan3, Erin B Treemarcki4, Stephanie Armendariz5, Tracey B Wright6, Chetna Godiwala5, Matthew L Stoll7, Rui Xiao8, Daniel Lovell9. 1. University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia. 2. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. University of Minnesota Masonic Children's Hospital, Minneapolis. 4. University of Utah and Primary Children's Hospital, Salt Lake City. 5. Scottish Rite Hospital for Children, Dallas, Texas. 6. University of Texas Southwestern Medical Center and Scottish Rite Hospital for Children, Dallas. 7. University of Alabama at Birmingham. 8. University of Pennsylvania, Philadelphia. 9. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
OBJECTIVE: Our objective was to develop and validate a composite disease flare definition for juvenile spondyloarthritis (SpA) that would closely approximate the clinical decision made to reinitiate or not reinitiate systemic therapy after therapy de-escalation. METHODS: Retrospective chart reviews of children with SpA who underwent systemic therapy de-escalation of biologic or conventional disease-modifying antirheumatic drugs were used to develop and validate the flare outcome. Data on independent cohorts for development (1 center) and validation (4 centers) were collected from large tertiary health care systems. Core measure thresholds and candidate disease flare outcomes were assessed using sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and the receiver operating characteristic (ROC) area under the curve (AUC), with physician assessment of active disease plus re-initiation of standard dose of systemic therapy as the reference standard. RESULTS: Of the candidate definitions, clinically meaningful worsening in ≥3 of the following 5 core measures performed best: caregiver/patient assessment of well-being; physician assessment of disease activity; caregiver/patient assessment of pain, physical function, and active joint count. The ROC AUC was 0.91, PPV 87.5%, NPV 98.1%, sensitivity 82.4%, and specificity 98.7%. Cronbach's α was 0.81, signifying internal consistency, and factor analysis demonstrated that the outcome measured 1 construct. The Juvenile SpA Flare measure had face validity according to 21 surveyed pediatric rheumatologists. The Juvenile SpA Flare had an ROC AUC of 0.85, a PPV of 92.3%, and an NPV of 96.8% in the validation cohort. CONCLUSION: There is initial support for the validity of the Juvenile SpA Flare measure as a tool to identify disease flare in juvenile SpA patients de-escalating therapy, and the measure is potentially applicable in clinical practice, observational studies, and therapeutic trials.
OBJECTIVE: Our objective was to develop and validate a composite disease flare definition for juvenile spondyloarthritis (SpA) that would closely approximate the clinical decision made to reinitiate or not reinitiate systemic therapy after therapy de-escalation. METHODS: Retrospective chart reviews of children with SpA who underwent systemic therapy de-escalation of biologic or conventional disease-modifying antirheumatic drugs were used to develop and validate the flare outcome. Data on independent cohorts for development (1 center) and validation (4 centers) were collected from large tertiary health care systems. Core measure thresholds and candidate disease flare outcomes were assessed using sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and the receiver operating characteristic (ROC) area under the curve (AUC), with physician assessment of active disease plus re-initiation of standard dose of systemic therapy as the reference standard. RESULTS: Of the candidate definitions, clinically meaningful worsening in ≥3 of the following 5 core measures performed best: caregiver/patient assessment of well-being; physician assessment of disease activity; caregiver/patient assessment of pain, physical function, and active joint count. The ROC AUC was 0.91, PPV 87.5%, NPV 98.1%, sensitivity 82.4%, and specificity 98.7%. Cronbach's α was 0.81, signifying internal consistency, and factor analysis demonstrated that the outcome measured 1 construct. The Juvenile SpA Flare measure had face validity according to 21 surveyed pediatric rheumatologists. The Juvenile SpA Flare had an ROC AUC of 0.85, a PPV of 92.3%, and an NPV of 96.8% in the validation cohort. CONCLUSION: There is initial support for the validity of the Juvenile SpA Flare measure as a tool to identify disease flare in juvenile SpA patients de-escalating therapy, and the measure is potentially applicable in clinical practice, observational studies, and therapeutic trials.
Authors: Timothy G Brandon; Brandon D Becker; Katherine B Bevans; Pamela F Weiss Journal: Arthritis Care Res (Hoboken) Date: 2017-03 Impact factor: 4.794
Authors: Angelo Ravelli; Alessandro Consolaro; Gerd Horneff; Ronald M Laxer; Daniel J Lovell; Nico M Wulffraat; Jonathan D Akikusa; Sulaiman M Al-Mayouf; Jordi Antón; Tadej Avcin; Roberta A Berard; Michael W Beresford; Ruben Burgos-Vargas; Rolando Cimaz; Fabrizio De Benedetti; Erkan Demirkaya; Dirk Foell; Yasuhiko Itoh; Pekka Lahdenne; Esi M Morgan; Pierre Quartier; Nicolino Ruperto; Ricardo Russo; Claudia Saad-Magalhães; Sujata Sawhney; Christiaan Scott; Susan Shenoi; Joost F Swart; Yosef Uziel; Sebastiaan J Vastert; Josef S Smolen Journal: Ann Rheum Dis Date: 2018-04-11 Impact factor: 19.103
Authors: Pamela F Weiss; Robert A Colbert; Rui Xiao; Chris Feudtner; Timothy Beukelman; Esi Morgan DeWitt; Ilaria Pagnini; Tracey B Wright; Carol A Wallace Journal: Arthritis Care Res (Hoboken) Date: 2014-12 Impact factor: 4.794
Authors: N Ruperto; A Ravelli; A Pistorio; C Malattia; S Cavuto; L Gado-West; A Tortorelli; J M Landgraf; G Singh; A Martini Journal: Clin Exp Rheumatol Date: 2001 Jul-Aug Impact factor: 4.473
Authors: David Thissen; Yang Liu; Brooke Magnus; Hally Quinn; Debbie S Gipson; Carlton Dampier; I-Chan Huang; Pamela S Hinds; David T Selewski; Bryce B Reeve; Heather E Gross; Darren A DeWalt Journal: Qual Life Res Date: 2015-06-29 Impact factor: 4.147
Authors: Hermine I Brunner; Marisa S Klein-Gitelman; Michael J Miller; Andrea Barron; Nicole Baldwin; Michael Trombley; Anne L Johnson; Angie Kress; Daniel J Lovell; Edward H Giannini Journal: J Rheumatol Date: 2005-01 Impact factor: 4.666
Authors: Janalee Taylor; Edward H Giannini; Daniel J Lovell; Bin Huang; Esi M Morgan Journal: Arthritis Care Res (Hoboken) Date: 2017-12-06 Impact factor: 4.794
Authors: Jaime Guzman; Andrew Henrey; Thomas Loughin; Roberta A Berard; Natalie J Shiff; Roman Jurencak; Adam M Huber; Kiem Oen; Kerstin Gerhold; Brian M Feldman; Rosie Scuccimarri; Kristin Houghton; Gaëlle Chédeville; Kimberly Morishita; Bianca Lang; Paul Dancey; Alan M Rosenberg; Julie Barsalou; Alessandra Bruns; Karen Watanabe Duffy; Susanne Benseler; Ciaran M Duffy; Lori B Tucker Journal: J Rheumatol Date: 2019-01-15 Impact factor: 4.666